Antiandrogen

Wyss Institute’s AminoX project receives funding from Northpond Labs to accelerate innovation in protein-based therapeutics

Retrieved on: 
Monday, April 8, 2024
Molecule, Research, Innovation, Patient, DNA, Wyss Institute, Engineering, Protein, Laboratory, Organic acid, Harvard University, CRISPR, Drug development, Wyss, Biological engineering, Therapy, Genetic code, FDA, Antiandrogen, Vocabulary, Fine chemical

This is the fourth Wyss project selected by Northpond Labs for additional funding.

Key Points: 
  • This is the fourth Wyss project selected by Northpond Labs for additional funding.
  • The Laboratory has previously funded the Wyss’ eRNA (now being commercialized by EnPlusOne Biosciences ), SomaCode , and Lab-on-a-Molecule projects.
  • “The AminoX platform has the potential to transform our ability to develop differentiated protein-based therapeutics by significantly expanding the vocabulary of building blocks that can be incorporated into biologics at high throughput.
  • We are thrilled that the AminoX team’s journey to the market will be accelerated by this support,” said Angelika Fretzen, Ph.D., M.B.A., the Wyss Institute’s Technology Translation Director & Chief Operating Officer.

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming 2024 ASCO Genitourinary Cancers Symposium (ASCO GU)

Retrieved on: 
Tuesday, January 16, 2024
Other Health, Men, General Health, Radiology, Pharmaceutical, Oncology, Consumer, Medical Devices, Health Technology, Biotechnology, Neurology, Health, Serum, Prostate cancer, Recurrence, Radiation, F 18, ASCO, Cancer, Risk, PSA, Lymph, ADT, FDA, Diarrhea, Blood pressure, Antiandrogen, Medical imaging

Blue Earth Diagnostics invites participants at the ASCO 2024 Genitourinary Cancers Symposium to attend the presentations above.

Key Points: 
  • Blue Earth Diagnostics invites participants at the ASCO 2024 Genitourinary Cancers Symposium to attend the presentations above.
  • For full session details and scientific presentation listings, please see the ASCO GU online program here .
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • Flotufolastat F 18 uptake is not specific for prostate cancer and may occur in other types of cancer, in non-malignant processes, and in normal tissues.

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Research, Neurology, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Science, Oncology, Blood pressure, San Diego Convention Center, Risk, Radiation, Diarrhea, Serum, ASTRO, F 18, Cancer, PET, ADT, Recurrence, Lymph, Annual general meeting, Exhibit, FDA, PSA, Antiandrogen, Prostate cancer, Medical imaging, Patient

Blue Earth Diagnostics invites participants at the 2023 ASTRO Annual Meeting to attend the presentations above and visit the company at Exhibit Booth 2223.

Key Points: 
  • Blue Earth Diagnostics invites participants at the 2023 ASTRO Annual Meeting to attend the presentations above and visit the company at Exhibit Booth 2223.
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • The performance of POSLUMA for imaging patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels.
  • Flotufolastat F 18 uptake is not specific for prostate cancer and may occur in other types of cancer, in non-malignant processes, and in normal tissues.

Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress

Retrieved on: 
Monday, September 11, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Partnership, Therapy, Impact, Food, PARP2, WRN, PARP1, EDT, Trial of the century, Science, Data analysis, Patient, Automation, Machine learning, TLR 7, Engineering, Eikon, Drug discovery, Morgan, AI, TLR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, VCP, Antiandrogen, Pharmaceutical industry, IND

“Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.

Key Points: 
  • “Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.
  • “Our advanced analytical tools have enabled Eikon to capitalize on near-term opportunities to bring new medicines to patients.
  • Eikon believes that adverse experiences associated with BDB001 treatment are manageable using Eikon’s proposed clinical dosing regimen.
  • Eikon anticipates initiating Phase 1 clinical studies of IMP1734 in the United States and other jurisdictions in the fourth quarter.

Blue Earth Diagnostics Highlights POSLUMA® (Flotufolastat F 18) Injection and Investigational 18F-Flotufolastat Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Retrieved on: 
Tuesday, June 20, 2023
Oncology, Health, Medical Devices, Neurology, Radiology, Pharmaceutical, Biotechnology, Blood pressure, Risk, Medical Affairs Bureau, Radiation, MBBS, SNMMI, Diarrhea, Lakeside, Serum, F 18, Clinical research, Cancer, ADT, FRCR, Recurrence, MD, Lymph, Exhibit, FDA, Therapy, PSA, MRCP, Antiandrogen, Prostate cancer, Medical imaging, Patient

Blue Earth Diagnostics invites participants at the 2023 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 6025.

Key Points: 
  • Blue Earth Diagnostics invites participants at the 2023 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 6025.
  • The Company is hosting a Satellite Symposium, “PSMA PET: Imaging Reimagined,” which will discuss the most recent innovations in PSMA-PET imaging for prostate cancer.
  • Featured speakers from Blue Earth Diagnostics are Eugene J. Teoh, MBBS, MRCP, FRCR, D.Phil., Chief Medical Officer, and Phillip Davis, MD, Vice President Clinical Science.
  • Blue Earth Diagnostics also has a Medical Affairs information booth at SNMMI, where attendees can learn about clinical trials for the Company and its sister company, Blue Earth Therapeutics.

Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Retrieved on: 
Wednesday, February 8, 2023
ADT, Resuscitation, Fatigue, Antiandrogen, Diagnosis, Cancer, History, Risk, PSA, Allergy, Dysgeusia, Patient, FDA, Lymph, Recurrence, Headache, Serum, Radiation, Radiation exposure, Prostate cancer, Medical imaging, Birth control

A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.

Key Points: 
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels.
  • Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.
  • The most frequently reported adverse reactions were headaches, dysgeusia and fatigue, occurring at rate of ≤2% during clinical studies with PYLARIFY.

Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network

Retrieved on: 
Monday, June 13, 2022
Australian Securities Exchange, Gallium, Dysplasia, PET, Paget, Company, PSMA, Pharmacy, PSA, Man, Nausea, MTR, Food, LinkedIn, TGA, TLX, Paget's disease, Dizziness, Prostate cancer, Physician, Chief executive officer, Serum, FDA, Patient, Cancer, Risk, Antiandrogen, Radiation, Diarrhea, Control, ADT, Degenerative disease, Plasma protein binding, Disclosure, ASX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lymph, Safety, Osteophyte, Medical imaging, Pharmaceutical industry, Animal, Telix

Illuccix is now available to order from 139 pharmacy sites across the United States, ensuring scheduling flexibility and patient access to advanced prostate cancer imaging.

Key Points: 
  • Illuccix is now available to order from 139 pharmacy sites across the United States, ensuring scheduling flexibility and patient access to advanced prostate cancer imaging.
  • The expansion of the distribution network facilitates broader patient access to Illuccix across the country, expanding availability into new regional markets that to date have had limited access to PSMA PET imaging.
  • Our goal is to ensure broad access to PSMA PET imaging from the largest metropolitan cities to regional areas and the expansion of the distribution network to include Jubilant Radiopharma puts an Illuccix scan within reach of even more patients in need."
  • "We are pleased to be able to expand our range and service to include Illuccix, and offer our customers the added convenience of PSMA PET imaging with Illuccix," says Renato Leite, President, Jubilant Radiopharmacies Division.

Telix and RefleXion Expand Partnership for Prostate Cancer Treatment

Retrieved on: 
Friday, June 10, 2022
Australian Securities Exchange, Gallium, Radiation, Dysplasia, Caregiver, PET, Paget, SRS, PSMA, Lymph, PSA, Man, Company, Nausea, MTR, Toxicity, Food, LinkedIn, TGA, Partnership, Cancer, Positron, TLX, IMRT, Paget's disease, Prostate cancer, Dizziness, Osteophyte, Serum, FDA, Patient, Hospital, Risk, Technology, Antiandrogen, Twitter, Diarrhea, Reflection, ADT, Degenerative disease, Plasma protein binding, ASX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Safety, SBRT, Medical imaging, Pharmaceutical industry, Telix, Control

RefleXion is exclusively partnering with Telix for 68Ga PSMA-PET imaging agents for use with BgRT.

Key Points: 
  • RefleXion is exclusively partnering with Telix for 68Ga PSMA-PET imaging agents for use with BgRT.
  • More than 60,000 men undergo external-beam radiotherapy for prostate cancer every year in the U.S. alone[2].
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.You may also report adverse reactions to Telix by calling1-844-455-8638or via email to [email protected] .

Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Serum, Risk, Wilms' tumor, Company, History, Dysgeusia, Radiation, Patient, Solution, Artificial intelligence, Bausch Health, FDA, Technetium, Recurrence, Diagnosis, Allergy, Opioid, Prostate cancer, Combat, Radiation exposure, Antiandrogen, ADT, Therapy, PSA, Headache, Intelligence, PSMA, Lymph, Cancer, Fatigue, Resuscitation, Medical imaging, Birth control

A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.

Key Points: 
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels.
  • The performance of PYLARIFY for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage.
  • PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues.

Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer

Retrieved on: 
Wednesday, May 11, 2022
Bausch Health, Antiandrogen, Lymph, Risk, Artificial intelligence, Advantage, Allergy, Securities Exchange Act of 1934, Solution, Opioid, Forward-looking statement, Molecular imaging, LJ, N, Company, Securities Act of 1933, Dysgeusia, Veni, vidi, vici, FDA, Drug Quality and Security Act, Radiation exposure, Diagnosis, Technetium, Intelligence, Private Securities Litigation Reform Act, Radiology, Headache, Fatigue, Radiofluorination, International Cancer Imaging Society, PSA, Prostate cancer, Serum, PSMA, Wilms' tumor, Meta-analysis, Resuscitation, Radiation, Systematic review, Cancer, ADT, Therapy, History, Recurrence, Medical imaging, Birth control, Patient

A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.

Key Points: 
  • A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
  • The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels.
  • Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?
  • PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.